Celldex Therapeutics, Inc. (NASDAQ:CLDX) Position Increased by Fisher Asset Management LLC

Fisher Asset Management LLC raised its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 4.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,492 shares of the biopharmaceutical company’s stock after buying an additional 954 shares during the period. Fisher Asset Management LLC’s holdings in Celldex Therapeutics were worth $852,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in CLDX. Kynam Capital Management LP boosted its holdings in Celldex Therapeutics by 23.1% during the third quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company’s stock worth $88,064,000 after buying an additional 600,000 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Celldex Therapeutics by 5.9% during the third quarter. Wellington Management Group LLP now owns 5,431,833 shares of the biopharmaceutical company’s stock worth $149,484,000 after buying an additional 300,406 shares in the last quarter. Eventide Asset Management LLC boosted its holdings in Celldex Therapeutics by 16.1% during the third quarter. Eventide Asset Management LLC now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $44,032,000 after buying an additional 222,260 shares in the last quarter. Rock Springs Capital Management LP boosted its holdings in Celldex Therapeutics by 18.6% during the third quarter. Rock Springs Capital Management LP now owns 500,101 shares of the biopharmaceutical company’s stock worth $13,763,000 after buying an additional 78,486 shares in the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in Celldex Therapeutics by 72.4% during the third quarter. Affinity Asset Advisors LLC now owns 150,000 shares of the biopharmaceutical company’s stock worth $4,128,000 after buying an additional 62,969 shares in the last quarter.

Celldex Therapeutics Stock Performance

Shares of NASDAQ:CLDX opened at $41.06 on Friday. The company has a market cap of $2.30 billion, a PE ratio of -14.11 and a beta of 1.60. Celldex Therapeutics, Inc. has a 52 week low of $22.11 and a 52 week high of $53.18. The firm has a 50 day simple moving average of $41.57 and a 200 day simple moving average of $37.05.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.19. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. The company had revenue of $4.13 million during the quarter, compared to the consensus estimate of $1.20 million. On average, equities analysts predict that Celldex Therapeutics, Inc. will post -2.85 earnings per share for the current year.

Analyst Ratings Changes

CLDX has been the subject of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Friday, March 22nd. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research report on Tuesday. Finally, Guggenheim upped their price target on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $66.00.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.